March 31, 2026

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...

The ASCO Post

March 24, 2026

Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence

Based on results from the phase III KEYNOTE-564 study,1 adjuvant pembrolizumab is currently a standard of care for patients with clear cell renal cell carcinoma who have an increased risk of recurrenc...

The ASCO Post

March 15, 2026

Dana-Farber Research News 04.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 - 15.

Dana-Farber

November 22, 2023

Adjuvant Everolimus Improves Recurrence-Free Survival in Very High–Risk Renal Cell Carcinoma

A secondary analysis from the phase III SWOG S0931 EVEREST trial found that adjuvant everolimus given to patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectom...

The ASCO Post

April 21, 2021

First-Line Nivolumab Plus Cabozantinib Improves Outcomes vs Sunitinib in Advanced Renal Cell Carcinoma

The combination of nivolumab plus cabozantinib was found to be superior to the former standard, sunitinib, in the first-line treatment of advanced or metastatic renal cell carcinoma, according to the ...

The ASCO Post

January 30, 2024

Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma

In a study presented at the 2024 ASCO Genitourinary Cancers Symposium, investigators compared the efficacy of immune checkpoint inhibitor–based therapies vs sunitinib as front-line treatment in Black ...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

May 09, 2024

Belzutifan in Previously Treated Advanced Renal Cell Carcinoma

On December 14, 2023, a new treatment for unresectable locally advanced or metastatic clear cell renal cell carcinoma was approved, showing favorable outcomes compared to existing therapy.

The ASCO Post

December 27, 2023

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

On December 14, the FDA approved an HIF-2α inhibitor for patients with advanced RCC following treatment with a PD-1 or PD-L1 inhibitor and a VEGF TKI.

The ASCO Post

June 27, 2025

Can a Urine Test Minimize Postoperative Scans for RCC Recurrence?

Researchers examined whether a urine test could accurately detect clear cell renal cell carcinoma recurrence at an early stage, according to findings presented at the European Association of Urology (...

The ASCO Post